Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer

Дата публикации: 01-07-2026 20:00:09

Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy—including a near doubling of progression-free survival compared with expectations with standard of care—in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer	5	7	02-07-2026
2	New targeted therapy shows promising early results in advanced pancreatic cancer	2	7	05-07-2026
3	Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions	0	5	23-06-2026
4	Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer	0	7	22-08-2024
5	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
6	Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma	0	5	09-07-2026
7	Doctors just found a way to slow one of the deadliest prostate cancers	7	8	22-10-2025
8	EMA Recommends Extension of Therapeutic Indications for Encorafenib	0	5	03-07-2026
9	EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin	0	5	19-06-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 7. Информативность: 8. Источник: medicalxpress.com.